Propafenone

A new antiarrhythmic agent

M. S S Chow, C. Lebsack, Daniel E. Hilleman

Research output: Contribution to journalReview article

16 Citations (Scopus)

Abstract

The chemical and pharmacologic properties, pharmacokinetics, drug interactions, clinical efficacy, adverse effects, and dosage of propafenone are reviewed. Propafenone is a class IC antiarrhythmic agent that is structurally similar to the β blockers but that has only weak β-blocking and calcium-channel-blocking activity. It is well absorbed after oral administration, but systemic bioavailability is only 12% after a 300-mg dose. Among extensive metabolizers (> 90% of the United States population), bioavailability seems to vary nonlinearly with dose and increases substantially with food; these effects are not seen in poor metabolizers. Elimination is primarily hepatic, with a mean elimination half-life after oral administration of 5.5 hours in extensive metabolizers and 17.2 hours in poor metabolizers. The relationship between plasma propafenone concentration and clinical response varies considerably among individual patients; therefore, plasma concentrations have limited usefulness in predicting efficacy or electrophysiologic effects. Propafenone is effective in treating ventricular tachycardia and in suppressing premature ventricular complexes (PVCs). It is less effective in the treatment of refractory ventricular tachycardia. Concurrent administration of digoxin, warfarin, or metoprolol with propafenone has been shown to increase the serum concentrations of those three drugs, while cimetidine slightly increases the propafenone concentrations. Additive pharmacologic effect can occur when lidocaine, procainamide, and quinidine are combined with propafenone. Overall, 21% to 32% of patients experience adverse effects, with 3% to 7% of these serious enough to warrant discontinuing therapy. The most common adverse effects are dizziness or lightheadedness, metallic taste, and nausea and vomiting; the most serious adverse effects are proarrhythmic events. The initial dosage of the treatment of ventricular arrhythmias is 150 mg every eight hours for both rapid and poor metabolizers; increases should be made gradually over a three- to four-day period. For maintenance therapy; 450 to 900 mg/day orally in three or four divided doses has been shown to be effective. Propafenone is an effective and generally well tolerated antiarrhythmic agent for the treatment of PVCs and for initial treatment of ventricular tachycardia.

Original languageEnglish
Pages (from-to)869-877
Number of pages9
JournalClinical Pharmacy
Volume7
Issue number12
StatePublished - 1988
Externally publishedYes

Fingerprint

Propafenone
Ventricular Tachycardia
Ventricular Premature Complexes
Dizziness
Biological Availability
Oral Administration
Therapeutics
Taste Disorders
Procainamide
Metoprolol
Quinidine
Digoxin
Cimetidine
Warfarin
Calcium Channels
Lidocaine
Drug Interactions
Nausea
Vomiting
Half-Life

All Science Journal Classification (ASJC) codes

  • Pharmaceutical Science

Cite this

Chow, M. S. S., Lebsack, C., & Hilleman, D. E. (1988). Propafenone: A new antiarrhythmic agent. Clinical Pharmacy, 7(12), 869-877.

Propafenone : A new antiarrhythmic agent. / Chow, M. S S; Lebsack, C.; Hilleman, Daniel E.

In: Clinical Pharmacy, Vol. 7, No. 12, 1988, p. 869-877.

Research output: Contribution to journalReview article

Chow, MSS, Lebsack, C & Hilleman, DE 1988, 'Propafenone: A new antiarrhythmic agent', Clinical Pharmacy, vol. 7, no. 12, pp. 869-877.
Chow, M. S S ; Lebsack, C. ; Hilleman, Daniel E. / Propafenone : A new antiarrhythmic agent. In: Clinical Pharmacy. 1988 ; Vol. 7, No. 12. pp. 869-877.
@article{170f4b49ede14282a85c766ba9f5ee3a,
title = "Propafenone: A new antiarrhythmic agent",
abstract = "The chemical and pharmacologic properties, pharmacokinetics, drug interactions, clinical efficacy, adverse effects, and dosage of propafenone are reviewed. Propafenone is a class IC antiarrhythmic agent that is structurally similar to the β blockers but that has only weak β-blocking and calcium-channel-blocking activity. It is well absorbed after oral administration, but systemic bioavailability is only 12{\%} after a 300-mg dose. Among extensive metabolizers (> 90{\%} of the United States population), bioavailability seems to vary nonlinearly with dose and increases substantially with food; these effects are not seen in poor metabolizers. Elimination is primarily hepatic, with a mean elimination half-life after oral administration of 5.5 hours in extensive metabolizers and 17.2 hours in poor metabolizers. The relationship between plasma propafenone concentration and clinical response varies considerably among individual patients; therefore, plasma concentrations have limited usefulness in predicting efficacy or electrophysiologic effects. Propafenone is effective in treating ventricular tachycardia and in suppressing premature ventricular complexes (PVCs). It is less effective in the treatment of refractory ventricular tachycardia. Concurrent administration of digoxin, warfarin, or metoprolol with propafenone has been shown to increase the serum concentrations of those three drugs, while cimetidine slightly increases the propafenone concentrations. Additive pharmacologic effect can occur when lidocaine, procainamide, and quinidine are combined with propafenone. Overall, 21{\%} to 32{\%} of patients experience adverse effects, with 3{\%} to 7{\%} of these serious enough to warrant discontinuing therapy. The most common adverse effects are dizziness or lightheadedness, metallic taste, and nausea and vomiting; the most serious adverse effects are proarrhythmic events. The initial dosage of the treatment of ventricular arrhythmias is 150 mg every eight hours for both rapid and poor metabolizers; increases should be made gradually over a three- to four-day period. For maintenance therapy; 450 to 900 mg/day orally in three or four divided doses has been shown to be effective. Propafenone is an effective and generally well tolerated antiarrhythmic agent for the treatment of PVCs and for initial treatment of ventricular tachycardia.",
author = "Chow, {M. S S} and C. Lebsack and Hilleman, {Daniel E.}",
year = "1988",
language = "English",
volume = "7",
pages = "869--877",
journal = "Clinical Pharmacy",
issn = "0278-2677",
publisher = "American Society of Hospital Pharmacists",
number = "12",

}

TY - JOUR

T1 - Propafenone

T2 - A new antiarrhythmic agent

AU - Chow, M. S S

AU - Lebsack, C.

AU - Hilleman, Daniel E.

PY - 1988

Y1 - 1988

N2 - The chemical and pharmacologic properties, pharmacokinetics, drug interactions, clinical efficacy, adverse effects, and dosage of propafenone are reviewed. Propafenone is a class IC antiarrhythmic agent that is structurally similar to the β blockers but that has only weak β-blocking and calcium-channel-blocking activity. It is well absorbed after oral administration, but systemic bioavailability is only 12% after a 300-mg dose. Among extensive metabolizers (> 90% of the United States population), bioavailability seems to vary nonlinearly with dose and increases substantially with food; these effects are not seen in poor metabolizers. Elimination is primarily hepatic, with a mean elimination half-life after oral administration of 5.5 hours in extensive metabolizers and 17.2 hours in poor metabolizers. The relationship between plasma propafenone concentration and clinical response varies considerably among individual patients; therefore, plasma concentrations have limited usefulness in predicting efficacy or electrophysiologic effects. Propafenone is effective in treating ventricular tachycardia and in suppressing premature ventricular complexes (PVCs). It is less effective in the treatment of refractory ventricular tachycardia. Concurrent administration of digoxin, warfarin, or metoprolol with propafenone has been shown to increase the serum concentrations of those three drugs, while cimetidine slightly increases the propafenone concentrations. Additive pharmacologic effect can occur when lidocaine, procainamide, and quinidine are combined with propafenone. Overall, 21% to 32% of patients experience adverse effects, with 3% to 7% of these serious enough to warrant discontinuing therapy. The most common adverse effects are dizziness or lightheadedness, metallic taste, and nausea and vomiting; the most serious adverse effects are proarrhythmic events. The initial dosage of the treatment of ventricular arrhythmias is 150 mg every eight hours for both rapid and poor metabolizers; increases should be made gradually over a three- to four-day period. For maintenance therapy; 450 to 900 mg/day orally in three or four divided doses has been shown to be effective. Propafenone is an effective and generally well tolerated antiarrhythmic agent for the treatment of PVCs and for initial treatment of ventricular tachycardia.

AB - The chemical and pharmacologic properties, pharmacokinetics, drug interactions, clinical efficacy, adverse effects, and dosage of propafenone are reviewed. Propafenone is a class IC antiarrhythmic agent that is structurally similar to the β blockers but that has only weak β-blocking and calcium-channel-blocking activity. It is well absorbed after oral administration, but systemic bioavailability is only 12% after a 300-mg dose. Among extensive metabolizers (> 90% of the United States population), bioavailability seems to vary nonlinearly with dose and increases substantially with food; these effects are not seen in poor metabolizers. Elimination is primarily hepatic, with a mean elimination half-life after oral administration of 5.5 hours in extensive metabolizers and 17.2 hours in poor metabolizers. The relationship between plasma propafenone concentration and clinical response varies considerably among individual patients; therefore, plasma concentrations have limited usefulness in predicting efficacy or electrophysiologic effects. Propafenone is effective in treating ventricular tachycardia and in suppressing premature ventricular complexes (PVCs). It is less effective in the treatment of refractory ventricular tachycardia. Concurrent administration of digoxin, warfarin, or metoprolol with propafenone has been shown to increase the serum concentrations of those three drugs, while cimetidine slightly increases the propafenone concentrations. Additive pharmacologic effect can occur when lidocaine, procainamide, and quinidine are combined with propafenone. Overall, 21% to 32% of patients experience adverse effects, with 3% to 7% of these serious enough to warrant discontinuing therapy. The most common adverse effects are dizziness or lightheadedness, metallic taste, and nausea and vomiting; the most serious adverse effects are proarrhythmic events. The initial dosage of the treatment of ventricular arrhythmias is 150 mg every eight hours for both rapid and poor metabolizers; increases should be made gradually over a three- to four-day period. For maintenance therapy; 450 to 900 mg/day orally in three or four divided doses has been shown to be effective. Propafenone is an effective and generally well tolerated antiarrhythmic agent for the treatment of PVCs and for initial treatment of ventricular tachycardia.

UR - http://www.scopus.com/inward/record.url?scp=0024207994&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024207994&partnerID=8YFLogxK

M3 - Review article

VL - 7

SP - 869

EP - 877

JO - Clinical Pharmacy

JF - Clinical Pharmacy

SN - 0278-2677

IS - 12

ER -